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Reduction of anxiety-like and depression-like
behaviors in rats after one month of drinking
Aronia melanocarpa berry juice
Mirko Tomić,*a Đurđica Ignjatović,a Gordana Tovilović-Kovačević,a
Dijana Krstić-Milošević,a Slavica Ranković,b Tamara Popovićb and Marija Glibetićb
The treatment of mood and anxiety disorders by nutraceuticals is gaining growing awareness. Berries of
Aronia melanocarpa (Black chokeberry) and their extracts, exceptionally abundant in diverse phenolic
compounds, have become famous for the highest in vitro antioxidant activity among fruits and notable
health benefits (e.g. anti-diabetic, anti-inflammatory, cardioprotective). This study was designed to investi-
gate the behavioral effects of month-long unlimited consumption of Aronia master juice (AJ) and/or juice
reconstruct without polyphenols (RJ), in young male rats. AJ was initially evaluated for its content of phe-
nolic compounds by spectrophotometric assays and HPLC-DAD. Rats that were supplied with three
various water concentrations of AJ and RJ, respectively: 20% + 0% (ARO group), 5% + 15% (RAJ) and 0 +
20% (PLC), were compared with those which consumed only water (CTL). Daily drinking of AJ solution
was significantly elevated from the second or third week onward, which was most expressed in the ARO
group. Only this group displayed behavioral variations, manifested by certain hyperactivity in open field
tests and prominent reductions of anxiety-like behaviors in the elevated plus maze. The ARO rats also
expressed an alleviation of depression-like behavior in forced swimming tests. These findings demonstrate
the beneficial behavioral effects of the one-month-long free drinking of phenolic-rich AJ in rats (>20 ml
per kg b. mass daily) that may be recognized as stimulating, anxiolytic-like and antidepressant-like. The
in vitro assays suggested that MAO-A/MAO-B inhibitions by the phenolic compounds of AJ might be the
possible in vivo mechanisms for such behavioral actions.
1. Introduction
Medical literature suggests that mental illnesses have become
almost epidemic in the developed world.1 Based on clinical
documentation, it was estimated that nearly 20% of both the
adult and youth population in the USA had some form of
mental ailment in 2013.2 Mood and anxiety disorders are two
kinds of psychiatric diseases that attract most of the attention
of the public and medical community, which is based on the
evidence that more than half of mankind may be affected by
either of these complaints during their life.1 Besides psy-
chotherapy, the first-line option in the management of these
illnesses is pharmacotherapy, where a growing number of psy-
choactive drugs exerts a substantial degree of beneficial
effects.3,4 Unfortunately, most of these drugs are commonly
associated with unwanted side-effects and many individuals
exhibit refractory or intolerant responses.1,3,4 Therefore, a
certain part of research on psychiatric diseases has focused on
the investigation of alternative therapies or adjunctive strat-
egies, which could improve clinical outcomes.5 The use of
nutraceuticals is one of the main approaches to that effect.5–8
The Aronia shrub, a member of the Rosaceae family, has
become a very popular cultivar in Eastern and Northern
Europe, where it is grown as an ornamental plant and indus-
trial source of natural coloring agents.9 The berry of Aronia
melanocarpa Elliott (Black chokeberry; the genus name Aronia
has been replacing this common name) is rich source of poly-
phenols, especially anthocyanins, which are correlated with
high antioxidant activity.9,10 Aronia has a simple anthocyanin
spectrum, consisting almost exclusively of cyanidin glycosides
such as cyanidin-3-arabinoside and cyanidin-3-galactoside, but
has a manifold higher anthocyanin content in comparison
with other berry fruits.10,11 Proanthocyanidins and hydroxycin-
namic acids (chlorogenic and neochlorogenic acids) are also
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found in greater amounts while flavonols (quercetin glyco-
sides) and flavan-3-ols (epicatechin) are usually present as
minor components in Aronia berries.10,12 A number of experi-
mental and clinical studies revealed that anthocyanins them-
selves, such as anthocyanin-rich Aronia extracts, exhibited
diverse potential health benefits, including cardioprotective,
anti-diabetic and anti-inflammatory effects.9,13–15 Some
limited studies have also shown the effects of Aronia juices on
the behavior and cognitive functions of experimental
animals.16,17 Our observation that certain other polyphenol-
rich fruit extracts, although lower in phenolics when compared
to Aronia, have provoked a number of animal and human
studies that investigated their behavioral/psychological
effects,18–21 inspired us to explore those particular influences
of the juice of Aronia.
This behavioral study was carried out on young male rats,
which were provided for one month with unlimited consump-
tion of water dilutions (20%, v/v) of one of the following:
master Aronia juice (AJ) with a high concentration of phenolic
compounds, juice reconstruct without phenolic compounds
(RJ), or their combination (AJ : RJ = 1 : 3), where the control
group of animals was supplied with pure water. The influences
of the drinking variants on the overall activity and locomotion,
as well as on anxiety-like and depression-like behaviors, were
evaluated using appropriate animal behavioral models and are
discussed later. AJ was originally assayed for total phenolic
constituents and proanthocyanidins, while the particular phe-
nolic compounds were identified and quantified by the HPLC-
DAD method. The capacity of AJ to inhibit in vitro mono-
amine-oxidase enzymes, MAO-A and MAO-B, was estimated
and compared with analogous effects of the several phenolic
compounds found in AJ. The relations between the potential
in vivo MAO inhibition by the phenolic compounds of Aronia
and the experimental behavioral parameters registered in this
study are discussed.
2. Materials and methods
2.1 Materials
A commercial product (“Nutrika”, Belgrade, Serbia), obtained
by pressing of fresh Aronia berries and presented as a pure and
concentrated Aronia master juice (AJ), was used to prepare
drinking solutions in our lab. The manufacturer’s analytical
data for the AJ batch used in this study, regarding the nutri-
tional values of the most abundant components of AJ, were
used to prepare RJ. It contained the exact same amounts of
particular sugars, organic acids, minerals and vitamins as AJ,
but without the bioactive phenolics (in g L−1): glucose 45.0,
fructose 28.0, sorbitol 50.0, citric acid 1.21, K-citrate-monohy-
drate 6.0; in mg L−1: vitamin C 29.2, vitamin B1 0.38, vitamin
B2 0.71, vitamin B6 0.44, niacin 0.39, CaCl2 × 2H2O 559, MgCl2
550, NaCl 760. Both master beverages, AJ and RJ, were stored
at 4 °C during the study. All chemical reagents applied were of
analytical grade and produced either by “Sigma” (USA) or
“Serva” (Germany).
2.2 Analysis of phenolic compounds in AJ
The total phenolics in AJ were determined by a modified Folin-
Ciocalteu method and presented in mg L−1 of gallic acid
equivalents.22,23 Identification and quantification of individual
phenolic compounds were performed by chromatographic ana-
lysis (Agilent series 1100 HPLC instrument with a DAD detec-
tor) on a reverse phase Zorbax SB-C18 (Agilent) analytical
column (250 mm × 4.6 mm i.d., 5 µm particle size).23,24 Before
its injection into the HPLC system, AJ was filtered through a
0.45 μm membrane filter. The analysis of flavonoids and
hydroxycinnamic acids was performed with a mobile phase
that consisted of solvent A (1%, v/v solution of orthophospho-
ric acid in water) and solvent B (acetonitrile) using an elution
gradient according to the previously published method:
90–80% A 0–5 min, 80% A 5–20 min, 80–40% A 20–30 min,
40–0% A 30–35 min.24,25 The injection volume was 5 µl. Detec-
tion wavelengths were set at 260 and 350 nm, and the flow rate
was 1 ml min−1. Quantification was performed using standar-
dized calibration curves of flavonoids (rutin, hyperoside and
isoquercetin) and hydroxycinnamic acids (chlorogenic and
neochlorogenic acids). The anthocyanin analysis utilized a
mobile phase that consisted of solvent A (10% of formic acid
in water) and solvent B (acetonitrile) with an elution profile as
follows: 99% A 0–0.5 min, 99–93% A 1–4 min, 93–90% A
4–7 min, 90–86% A 7–11 min, 86–75% A 11–15 min, 75–60% A
15–18 min, 60–25% A 18–22 min, 25% A 22–25 min. Detection
wavelengths were set at 290, 350 and 520 nm, and the flow rate
was 1 ml min−1. The contents of cyanidin-3-O-glucoside and
cyanidin-3-O-arabinoside were determined using calibration
curves, while cyanidin-3-O-galactoside and cyanidin-3-O-xylo-
side were quantified in equivalents of cyanidin-3-O-arabino-
side. All experiments were repeated at least two times. The
results are presented as mg L−1 of AJ.
Total proanthocyanidins were determined spectrophotome-
trically by a slightly modified vanillin assay.26 Namely, 20 µl of
the 2% AJ in methanol in duplicate, or a range of concen-
trations of (+)-catechin in methanol, were mixed with 100 µl of
working vanillin reagent (0.5% vanillin and 4% HCl in metha-
nol). After 20 min at 30 °C, their absorbencies were measured
at 500 nm (A500). The contents of proanthocyanidins in AJ
were expressed as (+)-catechin equivalents in mg L−1.
2.3 Animals and treatments
Male adult Wistar rats, 4 months old, weighing 370–430 g,
provided by the vivarium of the Institute for Biological
Research, Belgrade, Serbia, were used in this study. The
animals were kept in groups of 3–4 per cage (42 × 26 ×
18 cm), under controlled conditions (room temperature
23–25 °C, 12 h light-dark cycle, food and drinking solutions
ad libitum). All animal procedures were in compliance with
Directive 2010/63/EU on the protection of animals used for
experimental and other scientific purposes. They were
approved by the Ethical Committee for the Use of Laboratory
Animals of the Institute for Biological Research “Siniša Stan-
ković”, University of Belgrade.
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Rats were randomly assigned to 3 experimental groups of 8
animals each, and one control group (N = 12). The experi-
mental groups were supplied with different drinking solutions,
prepared daily as combinations of AJ and RJ in tap water (v/v):
(1) ARO, contained 20% AJ; (2) RAJ, 5% AJ + 15% RJ; (3) PLC,
20% RJ. The control group (CTL) consumed tap water. The rats
were allowed to drink these solutions or water for the next 34
days, without restrictions. The amounts of the consumed
drinking solutions and food were estimated daily per cage and
calculated weekly per experimental group. Individual body
masses, which had been measured before (Day-1) and at the
end of the study (Day35), were used to determine the average
gain of body mass (±S.E.M.) for each experimental group. All
animals were consuming commercial rat chow (Veterinarski
zavod Subotica, Serbia; 20% of proteins). On the days: -1, 31,
32 and 34, appropriate behavioral tests were performed (09 h–
13 h), when rat activities were registered in a quiet room with
shaded illumination, by video recording. Most of the behavior-
al parameters were detected and analyzed by ANY-maze Video
tracking system (4.13; Stoelting, USA) while the remaining be-
havioral features were observed and recounted by a proficient
examiner, who was unaware of group qualification of the rats.
All parts of the apparatus that came in contact with the
animals were cleaned with 10% alcohol at the end of each
session.
2.4 Behavioral tests
2.4.1 Open field test (OFT). This test was used to estimate
average ambulation of each rat on Day-1 and Day31 of the
study, when they were allowed to move freely in a plastic open-
box (44 × 44 × 35 cm). The movements of single rats in four
adjacent boxes were simultaneously registered by a PC-
connected camera positioned centrally above, for 20 min. The
ANY-maze software evaluated animal activities according to
two chosen parameters: (1) the measure of overall activity,
presented by the percentage of total time when the animal was
active, and (2) locomotion, by the distance traveled (in m).27
The third analyzed parameter, (3) number of rearings (stand-
ing upright on the hind legs), which reflected vertical activity,
was counted during observation of the video recordings.
2.4.2 Elevated plus maze (EPM). This is a typical test based
on the innate fear of rodents of open and elevated spaces,
which is applied to detect anxiety-like behaviors and to evalu-
ate anxiolytic-like treatments in experimental animals.27 The
EPM apparatus consisted of a cross-shaped Plexiglas platform
with two opposite open arms (OA, 50 × 10 cm) and two oppo-
site closed arms (CA, 50 × 10 cm) with 40 cm walls, connected
by a central platform (CP, 10 × 10 cm) and elevated 50 cm from
the floor.27 On the Day32, each rat was placed in a CP facing
one of the CAs. Their movements were recorded for the next
5 min with a video camera mounted vertically above the appar-
atus. The level of rat anxiety was estimated by the periods
spent in OA and number of entries into OA, which were quan-
tified and presented in our test as % of OA time and % of OA
entries.27,28 Another two parameters, the number of entries in
CA and the time of immobility, were also used, as they may
reflect general activity and ambulation.28,29 While these four
parameters were estimated by ANY-maze software, the other
two ethological parameters were detected and counted by an
observer: the number of SAP (stretched attend posture; when a
rat stretches its head and shoulders before returning to its
initial position), which represented risk assessment, and the
number of head dips (when a rat scans over the side of an OA
towards the floor), as a reflection of exploratory behavior.28,30
A random half of CTL animals (n = 6), which were being
supplied with pure drinking water, was considered as a
primary control group with unmodified behavior (CTL). They
received saline (0.9% NaCl) 1 ml per kg of b. mass (ip), 60 min
before the test, and the same was applied to all rats in the
experimental groups. The other 6 CTL rats were treated with
1 mg kg−1 of anxiolytic diazepam in saline, in the same
manner as the other groups. They were considered as a refer-
ence treatment group with reduced anxiety-like behaviors
(DZP).
2.4.3 Forced swimming test (FST). This test is based on the
observations that rats forced to swim in an inescapable space
express characteristic behavior of immobility, when they are
floating in water and making only those movements that are
necessary to keep their heads afloat. Such immobility reflects a
state of despair or a depression-like form of behavior that can
be reduced by human antidepressant drugs.27 Increases in
active responses, such as climbing or swimming, and
reduction in immobility, are considered as behavioral profiles
consistent with an antidepressant-like action31 In this adap-
tation of the original FST,27,32 each rat was trained on Day33
for 12 min, by being forced to swim in an open glass cylinder
(R = 20 cm, L = 48 cm), containing 25 cm of water maintained
at 23–25 °C. On Day34, rats were individually placed into the
water tank for 6 min and their activities were registered from a
vertical position by video camera. The active periods of swim-
ming (defined as movement throughout the swim chamber)
and climbing (upward-directed movements of the forepaws
along the side of the swim chamber), together with the
immobile-periods, were later observed, registered and sum-
marized by a trained observer, using ANY-maze software. One
hour before their individual test, a random 6 CTL rats and
each rat of the 3 experimental groups were injected with saline
(ip; 1 ml per kg b. mass), while another 6 CTL rats were
injected with 15 mg kg−1 of antidepressant imipramine in the
same manner. The first group represented the basic control
group (CTL) and the second group was considered as the refer-
ence treatment group with reduced depression-like behaviors
(IMI).
2.5 MAO assays
The effects of Aronia juice and phenolic compounds on in vitro
MAO activity were evaluated using MAO-Glo Assay V1401
(Promega; USA) as described elsewhere.33 This two-step bio-
luminescent assay was performed in 96-well flat-bottom assay
plates where the purified rat liver mitochondrial fraction was
used as a source of MAO enzymes.34 In the first step, the
mitochondrial microsomes were incubated with a substrate
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(concentrations were set at their Km values of 40 µM and 4 µM
for MAO-A and MAO-B, respectively) and various concen-
trations of the phenolic compounds (0.1 µM–100 µM/1 mM)
or AJ, for 1 h at room temperature. The dilutions of AJ in the
assay were adjusted to the concentration of total phenolic
compounds determined for AJ (6.484 g L−1), so that their
ranges of concentrations in the assay were 0.01–100 µg mL−1.
The reaction buffer for the MAO assay contained 100 mM
Hepes (pH 7.5) and 5% glycerol, and for MAO-B, the buffer
additionally contained 10% dimethyl sulfoxide (DMSO), which
was used to inhibit MAO-A and stimulate MAO-B activity. In the
second step, after the addition of reconstituted luciferin detec-
tion reagent used to generate and stabilize the luminescence,
the mixtures were incubated at room temperature for
20 minutes. Pargyline was used as a reference compound for
both assays. The luminescent signal was measured using a
Chameleon chemiluminescence reader (Hidex, Turku, Finland).
The results were presented as IC50 values in µg mL
−1 of AJ
phenolics, or in µM for the particular phenolic compounds.
2.6 Data presentation and statistical analysis
Experimental data are presented as mean ± S.E.M., in relation
to the number of animals. Statistical analyses of all experi-
mental data, as well as the determination of IC50 values for
MAO inhibition, were done by the Prism software (5.0; Graph-
Pad software, USA). Intergroup differences were evaluated by
either two-way (OFT) or one-way ANOVA, followed by Newman-
Keul’s post-hoc test for multiple comparisons (if p < 0.05). Two-
way Student’s t-test was used to compare homologous Day31
and Day-1 values (OFT).
3. Results
3.1 Characterization and quantification of phenolic
constituents in AJ
The qualitative and quantitative analyses of AJ are presented in
Table 1. Only the identified phenolic compounds with concen-
trations >10 mg L−1 are provided.
3.2 Quantitative parameters of eating, drinking and body
mass gain
The average daily consumptions of drinking solutions in the
experimental groups during this 5-week study are represented
in Table 2. They are shown in mL per animal, instead of ml
per body mass, considering the variable gains in body mass
during the study. Analysis by two-way ANOVA revealed a signifi-
cant influence of the week of the study (F(4,120) = 28.03, p <
0.0001) and of the contents of drinking solutions (F(3,120) =
41.31, p < 0.0001), but also of their interaction (F(12,120) =
8.78, p < 0.0001). These effects are reflections of the greatly
enhanced drinking of solutions with Aronia phenolics, where
only two groups supplemented with AJ showed significant
elevations of daily drinking from the 2nd (RAJ) or 3rd week
(ARO) onward. The consumed amount of the drinking solution
in the ARO group was 50–70% higher vs. CTL, and about
40–60% vs. PLC, throughout the 3rd, 4th and 5th week, while
this increase in the RAJ group went up to 30%.
Table 3 shows the overall consumptions of the liquids and
food in the experimental groups during the five weeks of the
study. Also, this table provides the consumed quantities of the
total phenolic compounds, proanthocyanidins and anthocya-
nins in g per kg of b. mass in each experimental group. These
calculations are based on the analytical data presented in
Table 1 and the volumes of the solutions that were drunk
weekly (Table 2). The volume-mass transformations are based
on the mass densities of 1.10, 1.09 and 1.02 g mL−1, estimated
for AJ, RJ and all drinking mixtures, respectively. Standard
deviations of these values were not obtained since it was not
possible to track individual consumptions within the group.
The variations of the average rat chow consumptions among
the groups were within 5%, which may indicate that they are
not significant. Otherwise, the amounts of the drinking solu-
tions consumed in the groups RAJ and ARO were between 13%
and 30% higher than the amounts in groups CTL and PLC,
which could be referred to as significant elevations. The calcu-
lated quantities of the phenolics that were consumed in the
ARO group were about 4.5 times larger than in the RAJ group.
Supplementary calculations for the period of the first 4 weeks
of the study pointed out that the average daily phenolic con-
sumptions per kg of rat body mass were: 30.8 and 133.0 mg
per kg per day in the RAJ and ARO groups, respectively. During
the 5th week of the study, when all behavioral tests were per-
formed, these amounts were 33.0 (RAJ) and 168.0 (ARO) in mg
per kg per day. The variations of the body mass gains among
the groups were significant [F(3,32) = 5.535, p < 0.0035, one-
way ANOVA], with conspicuous 60–70% enlargements in the
ARO group when matched with the CTL and RAJ groups, but
not in comparison with the PLC group.
Table 1 Quantities of phenolic compounds in Aronia melanocarpa fruit
juice (AJ). Data expressed as mean values (n = 2 or 3), standard error
<8% of mean values















a Folin-Ciocalteu method, concentration based upon gallic acid as
standard. bDetermined spectrophotometrically by the vanillin assay,
concentration based upon (+)-catechin as standard. c Single com-
pounds determined by HPLC/DAD. The flavonoids (rutin, hyperoside
and isoquercetin), cyanidin-3-O-galactoside and hydroxycinnamic
acids (chlorogenic and neohlorogenic acids) were used as standards.
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3.3 Open field test
Two of the parameters evaluated by OFT before the start of the
study, the distance traveled (Fig. 1A) and the active time
(Fig. 1B), did not show significant variations among the experi-
mental groups [F(3,32) = 0.901, P = 0.451 and F(3,32) = 1.309,
P = 0.288, respectively], while the influences of the one-month
treatments on these parameters were evident on Day31 [F(3,32)
= 3.917, P = 0.017 and F(3,32) = 2.924, P = 0.0488, respectively].
The post-hoc test revealed significant differences between the
groups: ARO and CTL (+35%, p < 0.05), as well as for ARO vs.
RAJ (+46%, p < 0.05), regarding the distance traveled. Also,
active time was enhanced in the ARO group in comparison
with both the CTL (+33%, p < 0.05) and RAJ (+32%, p < 0.05)
groups. The fluctuation of these parameters in the same
experimental group between Day31 and Day-1 were verified by
the Student’s t-test, which revealed significant increases of
both distances traveled (+22%, p = 0.040; Fig. 1A) and active
times (+20%, p = 0.032; Fig. 1B) only in the ARO group. The
rearings recorded in OFT (Fig. 1C) were not significantly
altered on both Day-1 and Day31 [F(3,32) = 1.231, P = 0.315
and F(3,32) = 1.139, P = 0.348, respectively], but there were
almost significant elevations of this parameter in the RAJ
(+56%, p = 0.053) and ARO (+40%, p = 0.059) groups, between
Day31 and Day-1.
3.4 Elevated plus maze
EPM was used on Day32 of the experiment to determine the
effects of treatments on the anxiety-like forms of rat behavior
(Fig. 2). Two parameters of EPM that reflect the opposite to
such behavior were significantly altered: % of time spent in
OA (F(4,31) = 5.874, p = 0.0012; Fig. 2A), with a significant
Table 3 Cumulative consumptions of drinking solutions, AJ, total phe-
nolics, proanthocyanidins, anthocyanins and rat chow, and average rat
body mass gains in the experimental groups
Experimental group: CTL PLC RAJ ARO
Consumption (g per kg b. mass) of:
Drinking solution 2813 2906 3273 3645
AJ 0 0 176 786
Phenolics 0 0 1.037 4.636
Proanthocyanidins 0 0 0.039 0.172
Anthocyanins 0 0 0.071 0.315
Rat chow 1775 1817 1718 1731
Body mass gain
(% of b. mass on Day-1)
4.8 ± 0.5 6.9 ± 0.6* 5.1 ± 0.7 8.1 ± 0.9*,#
Overall consumptions throughout 34 days of the experiment are
presented for the rat chow and for each of the drinking solutions,
where the consumed amounts of these solutions, AJ, total phenolics,
proanthocyanidins and anthocyanins of AJ, are shown in grams per kg
of average body mass [(Day-1 + Day35)/2]. Mass densities of AJ and RJ
were 1.10 and 1.09 g mL−1, respectively, while they were 1.02 g mL−1
for all drinking solutions except tap water. Average body mass gains in
each experimental group was estimated on Day35 and presented as
percentage of body mass on Day-1 ± S.E.M. (N = 8, or N = 12 for CTL)
*, p < 0.05 vs. CTL; #, p < 0.05 vs. RAJ by post hoc Newman-Keuls
multiple comparisons test.
Table 2 Daily consumptions of drinking solutions in 5 weeks of the experiment
Experimental group: week CTL PLC RAJ ARO
1st 30.33 ± 1.73a 30.00 ± 1.47a 33.25 ± 1.11a 30.24 ± 2.35a
2nd 39.50 ± 3.28a,* 35.70 ± 5.06a 39.28 ± 1.94a,* 35.60 ± 0.40a
3rd 32.88 ± 1.25a 39.10 ± 1.64b,* 42.40 ± 1.14b,** 57.42 ± 0.66c,***,#
4th 35.70 ± 1.65a 35.88 ± 1.80a 46.37 ± 2.19b,*** 55.17 ± 3.05c,***,#
5th 34.10 ± 2.10a 36.78 ± 1.09a 43.73 ± 0.24b,** 58.50 ± 0.76c,***,#
Experimental groups have been limitlessly supplied with tap water (CTL), and water dilutions of: 20% RJ (PLC), 5% AJ + 15% RJ (RAJ), and 20%
AJ (ARO). Values of the average daily consumptions of drinking solutions (in ml per animal) for each of 5 weeks of the experiment are presented
as mean ± S.E.M., which reflected daily variations within a week (N = 7 or 6). Values with different letters in the same row are significantly
different from each other (p < 0.05), while those that share the same letters are not (p > 0.05). The column statistics is presented with symbols:
*, p < 0.05; **, p < 0.01; ***, p < 0.001 vs. 1st week. #, p < 0.001 vs. 2nd week. Newman-Keuls multiple comparisons test was applied after two-way
ANOVA.
Fig. 1 Effects of month-long unlimited drinking of either tap water (CTL), 20% RJ (PLC), 5% AJ + 15% RJ (RAJ), or 20% AJ (ARO), on rat behavior in
OFT. The overall rat activities were registered during 20 min, before the start of the experiment (Day-1) and on Day31 of the study. Three OFT para-
meters, evaluated by ANY-maze software, are presented: (a) distance traveled, (b) percentage of active time, and (c) number of rearings, which
are expressed as group mean ± S.E.M. values (n = 12 or 8). *p < 0.05, vs. CTL, by one-way ANOVA post hoc Newman-Keuls multiple comparison test.
#p < 0.05, by two-way student’s t-test, Day31 vs. Day-1.
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increase in ARO vs. PLC (+215%; p < 0.05) and vs. RAJ (+150%;
p < 0.05), but not vs. CTL (+77%; p > 0.05), and % of OA
entries (F(4,31) = 10.4, p < 0.0001; Fig. 2B), which was more
strongly expressed in the ARO group (+176% vs. CTL, and
+132 vs. PLC; p < 0.001) than in the DZP group (+105% vs.
CTL, and +72 vs. PLC; p < 0.05). Two parameters of EPM that
may reflect general activity and ambulation, the number of
entries in CA (Fig. 3C) and the time of immobility (Fig. 3D),
were not substantially affected by the treatments (F(4,31) =
0.321, p = 0.861 and F(4,31) = 2.307, p = 0.080, respectively). It
was the same with the number of SAP (Fig. 3E), which rep-
resented risk assessment (F(4,31) = 0.321, p = 0.861). On the
contrary, the number of head dips (Fig. 3F), as a reflection of
exploratory behavior, was clearly influenced by the treatments
(F(4,31) = 4.584, p = 0.005), with significant elevations in the
ARO group vs. the CTL (+156%; p < 0.05), PLC (+105%; p <
0.05) and RAJ (+125%; p < 0.05) groups.
3.5 Forced swimming test
This test was used as a regular model for screening the anti-
depressant-like action of the treatments. The percentages of
time when animals were immobile during 6 min in the cylind-
rical water container, which represented a depression-like
form of behavior on Day34, are shown in Fig. 3A. There was a
very significant effect of the treatments on the immobile
periods in the FST (F(4,31) = 11.57, p < 0.0001). The post-hoc
test revealed that this parameter was significantly diminished
in both the ARO (−28% vs. CTL, and −23% vs. PLC; p < 0.001)
and IMI (−21% vs. CTL, and −16% vs. PLC; p < 0.01) group.
The influence of the treatments on the periods of active swim-
ming, which may be interpreted as the modulation of seroto-
nin (5-HT) neurotransmission,32 also appeared to be very
significant (F(4,31) = 21.15, p < 0.0001; Fig. 3B). This was an
outcome of exceptionally intensified swimming in the ARO
group (+133% vs. CTL, and +93% vs. PLC; p < 0.001), and of a
lesser swimming increase in the IMI group (+61% vs. CTL, and
+33% vs. PLC; p < 0.05). There was a modest effect of the treat-
ments on climbing behavior (F(4,31) = 3.90, p < 0.011; Fig 3C),
which indicated the levels of noradrenaline (NE) neurotrans-
mission,32 whereas only the rats that received imipramine
exhibited an increase in this parameter (p < 0.05, IMI vs. CTL
or PLC).
3.6 MAO assays
The abilities of AJ to inhibit MAO-A or MAO-B enzymes were
evaluated by the MAO-Glo Assays (Table 4). The IC50 values
(50% inhibitory concentration of the phenolic constituents in
µg L−1) were calculated in relation to the determined AJ con-
centration of the phenolics (0.65%). These data were com-
pared with the estimated IC50 values (in µM) for some of the
phenolic compounds that had been detected in AJ, and par-
gyline, as a referent MAO inhibitor. The MAO inhibiting
potency of AJ was more prominent for MAO-A than for
MAO-B enzymes, while quercetin was the only one among
the tested compounds that showed substantial MAO-A inhi-
bition (Table 4).
Fig. 2 Effects of month-long unlimited drinking of the experimental mixtures (details about the experimental groups are in the caption of Fig. 1) on
rat behavior in EPM. Each rat had been injected (ip; 1 ml per kg b. mass), one hour before the test was performed on Day32, with either 1 mg kg−1
diazepam (DZP; random 6 of 12 rats scheduled to drink only tap water) or saline (all other rats in the experimental groups and CTL). The rat behavior-
al parameters in EPM (as mean ± S.E.M. n = 6 or 8) were recorded for 5 min and evaluated with ANY-maze software or by observation, (a) percentage
of time spent in OA, (b) percentage of OA entries, (c) CA entries, (d) percentage of immobility time, (e) number of stretched attend postures (SAP)
and (f ) number of head dips. *p < 0.05, ***p < 0.001 vs. CTL; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. PLC, using one-way ANOVA followed by
Newman-Keuls post-hoc tests.
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The results of this study demonstrate that month-long con-
sumption of diluted AJ with a high level of phenolic com-
pounds may induce significant behavioral variations in male
rats, which were expressed as somewhat increased locomotion
and reduced anxiety-like and depression-like forms of behav-
ior. These behavioral modifications are related to unlimited
drinking of 20% AJ water dilution during one month (Table 2).
The concept of this study was quite different from the typical
nutritional-behavioral experimental studies, where specific
diets, rich in active ingredients, or purified natural com-
pounds, are provided to animals by monitored oral adminis-
trations. The approach applied here allowed the animals to
control their drinking habits in line with their general behav-
ior, which was analogous to human living patterns. Accord-
ingly, it was found that the adjunction of AJ in drinking water
induced very significant elevations of the daily drinking
amounts, from the 2nd/3rd week onward, which was more pro-
nounced in the ARO than in the RAJ group (Table 2). Only the
average group consumption of either mixture was being
tracked here, since it was not possible to control and deter-
mine individual drinking amounts. The progressive consump-
tions of both drinking mixtures with AJ over time revealed that
the rats developed increased affinity for this juice starting
from the 2nd/3rd week of the experiment. A possible expla-
nation for this may be increased thirst, which could be
induced by the bitter-astringent taste of AJ.35 However, the
main source of bitterness in AJ should be amygdalin,9 which
has been reported to have thirst-quenching capabilities.36
Moreover, in our pilot test, which was performed on 5 rats that
were allowed to drink 20% mixture of AJ in water for 20 days,
the average 30%-increment of the solution volume that was
drunk on Day20 (vs. Day-1), was completely reduced on Day21
(+2% vs. Day-1), when the rats were supplied with water only
(data unpublished). This information should not exclude a
temporary induction of thirst by sustained AJ consumption,
whereby the increased affinity for the particular component(s)
of Aronia juice may be another option.
The dietary effects of intensified drinking in this study
seem to promote body mass gain only for the ARO rats, when
compared to the CTL rats. It may be supposed that the highest
amount of the drinking solution that was drunk by the ARO
rats (+11% vs. RAJ and +25% vs. PLC) was the reason for their
body mass gain, since the consumption of rat chow was not
enhanced in this group (Table 3). On the other hand, the PLC
group showed certain elevations in both the rat chow eating
and body mass gain (Table 3). A similar dietary study, where
Fig. 3 The influence of month-long free drinking of the experimental
mixtures on the proportion of the periods of (a) immobility, (b) active
swimming, and (c) climbing, during 6 min in FST. (The same experi-
mental groups are presented as in Fig. 1 and 2.) One hour before the test
was performed on Day34, rats had been injected (ip; 1 ml per kg
b. mass) with either 15 mg kg−1 imipramine (IMI; random 6 of 12 rats on
water consumption) or saline (all other rats of CTL and the experimental
groups). Results are expressed as mean ± S.E.M. (n = 6 or 8). *p < 0.05,
**p < 0.01, ***p < 0.001 vs. CTL; #p < 0.05, ##p < 0.01, ###p < 0.001 vs.
PLC using one-way ANOVA followed by Newman-Keuls post-hoc tests.
Table 4 In vitro MAO-A and MAO-B inhibition by AJ and the specific
phenolic compounds
Compounds IC50 MAO A
a IC50 MAO B
a
AJ (µg L−1)b 2.2 58.4
Chlorogenic acid (µM) NDc NDc
Cyanidin-3-O-glucoside (µM) 96.3 209
Cyanidin-3-O-arabinoside (µM) 80.8 477
Quercetin (µM) 0.72 170
Rutin (µM) 260 105
(+)-Catechin (µM) 38.5 22.0
Pargyline (µM)d 6.7 0.22
a Each inhibitory activity is expressed as the mean of 50% inhibitory
concentration (IC50) of two experiments, which was obtained by an
interpolation of the concentration-inhibition curves. b Adjusted to the
concentration of phenolics in AJ, determined by Folin-Ciocalteu
method. cNot determined as the significant inhibition (>50%) for
the concentrations of up to 1mM. dUsed as a comparative MAO
inhibitor.
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Aronia extract did not alter food intake and water consumption
in rats that were fed a fructose-reach diet during 6 weeks while
their body mass gain and epididymal adipose weight were
reduced, suggests that Aronia might be beneficial in preventing
or decreasing obesity and the metabolic syndrome.37 Another
nutritional experiment showed a slight decrease in diet utili-
zation and growth for the rats on Aronia polyphenolic diets
relative to the control group.38 In an analogous human study,
when 100 ml of polyphenol-rich Aronia juice was consumed by
healthy women, they showed no changes in body weight or in
habitual dietary intake after 3 months on this regimen.39 The
discrepancies in the registered dietary effects of Aronia
between these and our study are coherent, having in mind the
different concepts related to unlimited vs. restricted consump-
tions of Aronia products. Taking all this into account, it seems
that the registered increase in affinity for the diluted AJ and its
extensive consumption solely contributed to the enhanced
body mass gains of the ARO rats, since this research did not
show that the free drinking of Aronia juice could stimulate
appetite and food intake.
The behavioral tests in this study were performed after the
one-month drinking regimen, during 4 consecutive days
(31–34). ARO was the only experimental group with significant
behavioral variations in this period. These effects should be
the result of drinking large amounts of phenolic-rich AJ, where
the calculated average amount consumed daily in the first 4
weeks was about 22 g per kg b. mass (133 mg per kg per daily
of phenolic constituents). During the 5th week, when the be-
havioral tests were performed, the ARO rats took over 30 g kg−1
of AJ daily (168 mg per kg per daily of phenolics), which was
about 5 times the AJ amount consumed in the RAJ group (6 g
kg−1). The behavioral consequences, registered by OFT in the
ARO group on Day31, were increased field activity and loco-
motion in relation to both the Day-1 and CTL group (Fig. 1A
and B), while the multiplication of rearings was almost signifi-
cant (+40% vs. Day-1, p = 0.059; Fig. 1C). On the other hand,
these parameters of activity were not significantly higher in
the ARO vs. PLC group (Fig. 1), which suggested that the phe-
nolic compounds were not solely responsible for that effect. A
comparative analysis of the results generated by OFT and EPM
indicates that the supposed hyperactivity of the ARO group
may be alternatively explained as an expression of the explora-
tory behaviors, which could be reinforced by the reduction of
innate anxiety. This assumption has its roots in the facts that
no hyperactivity of the ARO group was found in EPM (evalu-
ated by the number of CA entries and the percentage of immo-
bility time; Fig. 2C and D), while an elevation of the
parameters that are opposite to the anxiety-like behaviors (the
percentage of time spent in OA, the percentage of OA entries;
Fig. 2A and B) come together with an increased number of
head dips in the ARO group (Fig. 2F), which reflected explora-
tory behaviors.28 The enhancements of these three EPM para-
meters in the ARO group were exhibited toward three other
experimental groups (CTL, PLC and RAJ), whilst they were
similar to the acute effects of the anxiolytic diazepam (DZP;
1 mg kg−1). This evidence implies that only the intensive every-
day consumption of AJ may induce anxiolytic-like effects in
rats, which are detectable by EPM. The results of FST, present-
ing the reduction of immobile periods in ARO in comparison
to the other three groups (Fig. 3A), which was more convincing
than in the group acutely treated with the antidepressant imi-
pramine (IMI; 15 mg kg−1), suggest that everyday consumption
of AJ may also elicit antidepressant-like effects in rats. Since it
has been shown that the antidepressant-like actions in FST,
which were mediated by the stimulation of 5-HT neurotrans-
mission, induced the increase of active swimming period,
whereas the augmentation of NE neurotransmission was
related to the enhanced climbing activity,32 the here registered
activation of active swimming, but not of climbing in the ARO
group (Fig. 3B and C), suggests that this antidepressant-like
effect in rats may proceed from the stimulation of the neuro-
transmission mediated by 5-HT and not by NE. The absence of
both the increased climbing in FST and rat hyperactivity in
EPM may testify against a possibility that the OFT-referred
ambulatory stimulation in ARO could simulate anti-depressant
like effect in FST. Nevertheless, to clearly disprove (or not) this
plausibility, more sensitive and distinctive behavioral evalu-
ation of the antidepressant effect must be performed in the
further research on Aronia extracts. In any case, such
reductions of the anxiety-like and depression-like behaviors,
and a possible psycho-stimulation in animals, which followed
a sustained AJ consumption, may be interpreted as beneficial
from the human viewpoints.40,41
A brief glance at reviews in biomedical literature reveals a
substantial number of studies presenting the effects of natural
phenolic-rich sources, mainly of the flavonoid group, on the
behavior of experimental animals and humans.42,43 Hence,
there are only several studies where Aronia juices/extracts were
investigated in such a manner. The group of Valcheva-Kuzma-
nova found by passive avoidance tests that one-month con-
sumption of Aronia juice (up to 10 ml per kg b. mass daily)
could improve memory in rats, while the social interaction test
suggested some anxiolytic-like effects.16,17 However, they did
not find any effects on locomotion in OFT.16 This may be in
line with our evidence, where the RAJ group, with an approxi-
mate daily consumption of AJ in the range 5–6 ml kg−1, was
not overactive. The ARO group, which showed increased loco-
motion in our study, received more than 20 ml kg−1 of AJ daily.
Experiments with other polyphenol-rich fruit extracts showed
particular behavioral and cognitive effects. It has been
reported that low-molecular proanthocyanidins from grapes,
applied to mice for 7 days in doses of up to 50 mg kg−1,
exerted antidepressant-like effects in behavioral despair tests
but did not affect locomotor activity.19 The proposed anti-
depressant mechanism was dose-dependent inhibition of
MAO-A, and, to a lesser extent, of MAO-B, which induced
marked increases of serotonin, as well as of dopamine and
noradrenaline, in the frontal cortex, hippocampus and hypo-
thalamus.19 Another study using in vitro MAO assays did not
find significant effects of proanthocyanidins B1 and B2, but
revealed that anthocyanidins and anthocyanidin-3-glycosides
inhibited the activities of both MAO-A and MAO-B in the low
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micromolar range.20 The well-known medical applications of
MAO-A inhibitors as antidepressants and, in drug combi-
nations, as anti-anxiety drugs,44 combined with growing evi-
dence that flavonoids may inhibit MAO enzymes,45 has
motivated us to evaluate AJ and some of its phenolic constitu-
ents by in vitro MAO assays (Table 4). These assays revealed
reliable MAO-A inhibition by AJ (IC50 = 2.2 µg of Aronia pheno-
lics per L), which was expressed in relation to the determined
concentration of AJ phenolic compounds (6.48 g L−1). The
reconstituted phenolic-free Aronia juice, RJ, did not affect MAO
enzymes in the assay (data not included in Table 4). The levels
of MAO inhibition, generated by the specific phenolic com-
pounds in these assays, mostly corresponded to the literature
data20,45,46 where quercetin appeared to be the most potent
MAO-A inhibitor (IC50 = 0.72 µM). However, this flavonol was
found as aglycon only in traces in AJ, while the most abundant
phenolics in AJ showed poor or insignificant interactions with
MAO enzymes (Table 4). Obviously, it is challenging to esti-
mate the participation of individual phenolic compounds in
the resulting MAO inhibiting potency of AJ, especially with a
reasonable presumption that there was a synergistic action of
the various phenolics. Also, there is the question of the exact
AJ phenolic composition that was being consumed throughout
the study, knowing that the qualitative/quantitative analyses
had been performed on fresh juice, before the start of the
experiment. Considering both, the evidence that anthocyanin
stability in commercial Aronia juices was satisfactory (t1/2 = 6–7
weeks at 21 °C, 30–50 weeks at 4 °C),47 while all other phenolic
compounds in Aronia juices were found to be much more
stable than anthocyanins,48 together with the duration of our
experiment and the handling of AJ, the stable concentrations
of AJ phenolics is prospective throughout this study.
The greatest challenge is to extrapolate these in vitro data to
the complexity of a living organism. Dietary polyphenols are
highly sensitive to the mild alkaline conditions in the small
intestine and a good proportion of these compounds can be
transformed into other unknown and/or undetected structural
forms with different chemical properties and, consequently,
different bioaccessibility, bioavailability and biological
activity.49 Anthocyanins are poorly absorbed in the small intes-
tine, so they are recovered in blood and found in urine in
nanomolar concentrations, with the concern that conjugation
(glucuronidation and methylation) affects the biological
activity of anthocyanins in vivo.10,50 Proanthocyanidin particles
that may be absorbed through the gut barrier can be up to
trimer size and they constitute less than 5% of their total
amount.10 So, these two groups of polyphenols which are
present in moderate amounts in AJ are the least well absorbed.
Chlorogenic and neochlorogenic acids are found in significant
concentrations in Aronia, but esterification decreases their
intestinal absorption.10 Monomeric flavonols and flavan-3-ols,
like those usually detected in Aronia ((−)-epicatechin and quer-
cetin) are more efficiently absorbed than anthocyanins, but
their amounts in AJ are very low and it is not very likely that
they have a significant influence on plasma polyphenol con-
centrations.10,49 On the other hand, quercetin glucosides, such
as isoquercetin, have been shown to be much more quickly
absorbed and more bioavailable than the smaller quercetin
aglycone, or the larger quercetin glycosides such as rutin.51,52
The findings that glucoside chains are submitted to highly
effective hydrolysis in the small intestine endothelium indicate
that most of the ingested flavanols may enter circulation as
quercetin aglycones.52 So the therapeutic profiles of all flava-
nols found in Aronia may correspond to that of quercetin.
Another and still open query is related to the brain bioavail-
ability of polyphenols, dependent on their passing through the
blood-brain barrier,53 which is, however, beyond the scope of
this study. At all events, it is plausible that the combinations
of the original and transformed phenolic compounds of AJ
may attain rat circulation and pass the blood-brain barrier in
such concentrations that they could produce certain neuro-
chemical effects by synergism. A part of these effects would be
achieved by the central MAO inhibition (especially of MAO-A).
It may result preferentially in the up-regulation of central sero-
tonin and not of noradrenaline levels. Furthermore, the pre-
viously registered direct influences of particular bioflavonoids
on the neurotransmitter reuptake processes,18,21 GABA recep-
tors,45 even on acetyl-cholinesterase,54 suggest that these
additional interactions may contribute to the behavioral altera-
tions observed in ARO rats in this study. Only further investi-
gations may answer some of the questions regarding the exact
central influence of the phenolic constituents of Aronia.
5. Conclusions
The present findings demonstrate significant behavioral vari-
ations in male rats after one month of unlimited drinking of
diluted AJ (20%), when the average daily consumption of
Aronia phenolic compounds exceeded 130 mg per kg b. mass.
These changes were registered in animal models of behavior
and recognized as somewhat increased locomotion and the
reduction of anxiety-like and depression-like forms of behav-
ior. Although this study suggests that the central MAO-A inhi-
bition by the Aronia phenolic compounds may be important
for such behavioral effects, further research would shed more
light on these interactions.
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